The Swiss biopharmaceutical company Light Chain Bioscience has developed a novel and unique class of human, bispecific antibodies dubbed κλ bodies, so-called because they combine a κ light ...

Bispecific antibodies, which bind simultaneously to two different antigens, can attack tumors via novel mechanisms of action that cannot be evoked with combinations of conventional monoclonal ...

Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.

Both bispecific antibodies were administered on the same ... pharmacokinetics, pharmacodynamics, and immunogenicity. Progression-free survival was assessed. Investigator-assessed response was ...

Roche also included RG7827, a 4-1BBxFAP bispecific antibody, on the list of the candidates removed from its phase 1 pipeline. However, a Roche spokesperson clarified that the action relates to the ...

SAN DIEGO — In this video, Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, discussed research on the use of bispecific antibodies for lymphoma presented at ASH Annual ...

These payloads are delivered with bispecific antibodies that enable enhanced precision and functionality. As part of the strategic partnership, Biocytogen will provide a bispecific antibody ...

CytomX’s pipeline currently comprises seven therapeutic candidates across multiple treatment modalities, including antibody-drug conjugates (ADCs), T-cell engaging bispecific antibodies (TCBs ...

7-10, 2024; San Diego. Epcoritamab-bysp (Epkinly; Genmab, AbbVie) and glofitamab-gxbm (Columvi, Genentech) are bispecific antibodies currently approved in the U.S. for the treatment of relapsed or ...

(BHVN) and Merus N.V. (MRUS) announced a research collaboration and licensing agreement aimed at co-developing three innovative bispecific antibody drug conjugates (ADCs). The partnership will ...

The antibody-drug conjugate (ADC) arena continues to ring up deals, as Avenzo Therapeutics Inc. signed an exclusive license agreement with Duality Biotherapeutics Inc., whereby Avenzo will develop, ...

Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting CLDN18.2-positive tumor cells. It conditionally activates T cells through the 4-1BB signaling pathway in the tumor ...